Viktor Drvota

Chief Executive Officer & Director at Karolinska Development AB

Viktor Drvota

Viktor Drvota

Chief Executive Officer & Director at Karolinska Development AB

Overview
Career Highlights

Karolinska Development AB
Karolinska Development AB (Private Equity)

RelSci Relationships

421

Number of Boards

29

Birthday

01/01/1965

Age

56

Contact Data
Trying to get in touch with Viktor Drvota? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Viktor Drvota likely has professional access to. A relationship does not necessarily indicate a personal connection.

Procurator at KTH Chalmers Capital KB

Relationship likelihood: Strong

Chief Medical Officer at BioArctic AB

Relationship likelihood: Strong

Partner at Rosetta Capital Ltd.

Relationship likelihood: Strong

Co-Founder at Dilafor AB

Relationship likelihood: Strong

Chief Financial Officer at MiNA Therapeutics Ltd.

Relationship likelihood: Strong

Chief Financial Officer & Investment Director at Karolinska Development AB

Relationship likelihood: Strong

Senior Investment Director at Industrifonden

Relationship likelihood: Strong

Co-Founder at OssDsign AB

Relationship likelihood: Strong

Chief Executive Officer at Vitrolife AB

Relationship likelihood: Strong

Executive Chairman at ReWind Therapeutics NV

Relationship likelihood: Strong

Paths to Viktor Drvota
Potential Connections via
Relationship Science
You
Viktor Drvota
Chief Executive Officer & Director at Karolinska Development AB
Education
Ph.D. Unknown

Karolinska Institutet is a medical university in Solna within the Stockholm urban area, Sweden, and one of Europe's largest and most prestigious medical universities. It was founded in 1810 on Kungsholmen on the west side of Stockholm; the main campus was relocated decades later to Solna, just outside Stockholm. A second campus was established more recently in Flemingsberg, Huddinge, south of Stockholm.

Career History
Chief Executive Officer & Director
2015 - Current

Karolinska Development AB engages in the investment in pharmaceutical and medical technology companies. Its portfolio investments include Umecrine Cognition, Forendo Pharma, OssDsign, Modus Therapeutics, Dilafor, Aprea Therapeutics, Lipidor, Promimic, and Asarina Pharma. The company was founded in 2006 and is headquartered in Solna, Sweden.

Director
Current

OssDsign AB is a holding company, which designs, manufactures, and sells implants and material technology for bone regeneration. It specializes in cranioplasty and facial reconstructive surgery. Its products are titanium-reinforced calcium phosphate implants, including OssDsign Cranial, OssDsign Facial, and OssDsign Cranioplug. The company was founded by Håkan Gunnar Engqvist, Carl Thomas Engstrand, Bo Erik Qwarnstrom, and Jonas Åberg on February 4, 2011 and is headquartered in Uppsala, Sweden.

Deputy Director
Current

Promimic AB is a holding company that develops and markets implant surface modifications and synthetic bone based on a patented method for production of nano sized hydroxyapatite. It is a biomaterial company that improves surface modification and coating of new materials. The firm supplies nano-coatings for the implant industry. The company was founded by Per Gunnar Kjellin and Per Johan Martin Andersson in 2004 and is headquartered in Molndal, Sweden.

Boards & Committees
Director
Prior - 2011

SANOS Bioscience A/S is a Danish privately owned biotechnology company. Their business is to develop novel treatments for osteoporosis and other skeletal wasting diseases.It was founded in 2003 around patented and proprietary inventions from the Nordic Bioscience Group. This knowledge base includes a profound insight in the biology of skeletal tissue in health, molecular targets, biologicals, and lead compounds.SANOS is focused on the clinical development of SAN-134, an injectable formulation of the intestinal hormone glucagon-like peptide-2, GLP-2 for treatment of diseases with accelerated bone loss, such as osteoporosis.SANOS Bioscience A/S is headquarterd in Copenhagen, Denmark.

Director
2003 - Prior

InDex Pharmaceuticals Holding AB engages in the development of drugs for the treatment of diseases such as inflammation and cancer. It conducts research, technology development, and commercialization of scientific discoveries in the biomedical field. The firm also develops a platform of patent-protected substances, so-called deoxyribonucleic acid-based ImmunModulatory Sequences, with the potential to be used for the treatment of various immunological diseases. The company was founded by Oliver von Stein and Svante Rasmuson in 2000 and is headquartered in Stockholm, Sweden.

Director
2002 - 2016

SEB VC is an active, long-term manager which makes venture capital investments in growth companies in the technology, life science and industrial sectors, aiming to add competence and provide a network for investee companies. The firm focuses on companies which have a unique product or service with a sustainable competitive edge, a highly skilled management team who are also partners in the company and a business concept with international market potential.SEB VC takes a minority position in their investee companies, seeking board representation and making investments up to SEK 80 million.

Public Holdings
Restricted data only for RelSci Professional users.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Viktor Drvota. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Viktor Drvota's profile does not indicate a business or promotional relationship of any kind between RelSci and Viktor Drvota.